Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
Add more filters










Database
Language
Publication year range
1.
Proc Natl Acad Sci U S A ; 119(15): e2201632119, 2022 04 12.
Article in English | MEDLINE | ID: mdl-35380903

ABSTRACT

Current chemotherapy against Mycobacterium tuberculosis (Mtb), an important human pathogen, requires a multidrug regimen lasting several months. While efforts have been made to optimize therapy by exploiting drug­drug synergies, testing new drug combinations in relevant host environments remains arduous. In particular, host environments profoundly affect the bacterial metabolic state and drug efficacy, limiting the accuracy of predictions based on in vitro assays alone. In this study, we utilized conditional Mtb knockdown mutants of essential genes as an experimentally tractable surrogate for drug treatment and probe the relationship between Mtb carbon metabolism and chemical­genetic interactions (CGIs). We examined the antitubercular drugs isoniazid, rifampicin, and moxifloxacin and found that CGIs are differentially responsive to the metabolic state, defining both environment-independent and -dependent interactions. Specifically, growth on the in vivo­relevant carbon source, cholesterol, reduced rifampicin efficacy by altering mycobacterial cell surface lipid composition. We report that a variety of perturbations in cell wall synthesis pathways restore rifampicin efficacy during growth on cholesterol, and that both environment-independent and cholesterol-dependent in vitro CGIs could be leveraged to enhance bacterial clearance in the mouse infection model. Our findings present an atlas of chemical­genetic­environmental interactions that can be used to optimize drug­drug interactions, as well as provide a framework for understanding in vitro correlates of in vivo efficacy.


Subject(s)
Antitubercular Agents , Carbon , Cell Wall , Drug Interactions , Gene-Environment Interaction , Mycobacterium tuberculosis , Antitubercular Agents/pharmacology , Carbon/metabolism , Cell Wall/ultrastructure , Humans , Mycobacterium tuberculosis/drug effects , Mycobacterium tuberculosis/genetics , Mycobacterium tuberculosis/ultrastructure
2.
PLoS One ; 16(10): e0257911, 2021.
Article in English | MEDLINE | ID: mdl-34597304

ABSTRACT

Chemical-genetics (C-G) experiments can be used to identify interactions between inhibitory compounds and bacterial genes, potentially revealing the targets of drugs, or other functionally interacting genes and pathways. C-G experiments involve constructing a library of hypomorphic strains with essential genes that can be knocked-down, treating it with an inhibitory compound, and using high-throughput sequencing to quantify changes in relative abundance of individual mutants. The hypothesis is that, if the target of a drug or other genes in the same pathway are present in the library, such genes will display an excessive fitness defect due to the synergy between the dual stresses of protein depletion and antibiotic exposure. While assays at a single drug concentration are susceptible to noise and can yield false-positive interactions, improved detection can be achieved by requiring that the synergy between gene and drug be concentration-dependent. We present a novel statistical method based on Linear Mixed Models, called CGA-LMM, for analyzing C-G data. The approach is designed to capture the dependence of the abundance of each gene in the hypomorph library on increasing concentrations of drug through slope coefficients. To determine which genes represent candidate interactions, CGA-LMM uses a conservative population-based approach in which genes with negative slopes are considered significant only if they are outliers with respect to the rest of the population (assuming that most genes in the library do not interact with a given inhibitor). We applied the method to analyze 3 independent hypomorph libraries of M. tuberculosis for interactions with antibiotics with anti-tubercular activity, and we identify known target genes or expected interactions for 7 out of 9 drugs where relevant interacting genes are known.


Subject(s)
Anti-Bacterial Agents , Drug Discovery , Genes, Bacterial , Mycobacterium tuberculosis , Anti-Bacterial Agents/pharmacology , Genes, Bacterial/drug effects , Mycobacterium tuberculosis/metabolism
3.
mBio ; 10(4)2019 07 30.
Article in English | MEDLINE | ID: mdl-31363023

ABSTRACT

Despite the administration of multiple drugs that are highly effective in vitro, tuberculosis (TB) treatment requires prolonged drug administration and is confounded by the emergence of drug-resistant strains. To understand the mechanisms that limit antibiotic efficacy, we performed a comprehensive genetic study to identify Mycobacterium tuberculosis genes that alter the rate of bacterial clearance in drug-treated mice. Several functionally distinct bacterial genes were found to alter bacterial clearance, and prominent among these was the glpK gene that encodes the glycerol-3-kinase enzyme that is necessary for glycerol catabolism. Growth on glycerol generally increased the sensitivity of M. tuberculosis to antibiotics in vitro, and glpK-deficient bacteria persisted during antibiotic treatment in vivo, particularly during exposure to pyrazinamide-containing regimens. Frameshift mutations in a hypervariable homopolymeric region of the glpK gene were found to be a specific marker of multidrug resistance in clinical M. tuberculosis isolates, and these loss-of-function alleles were also enriched in extensively drug-resistant clones. These data indicate that frequently observed variation in the glpK coding sequence produces a drug-tolerant phenotype that can reduce antibiotic efficacy and may contribute to the evolution of resistance.IMPORTANCE TB control is limited in part by the length of antibiotic treatment needed to prevent recurrent disease. To probe mechanisms underlying survival under antibiotic pressure, we performed a genetic screen for M. tuberculosis mutants with altered susceptibility to treatment using the mouse model of TB. We identified multiple genes involved in a range of functions which alter sensitivity to antibiotics. In particular, we found glycerol catabolism mutants were less susceptible to treatment and that common variation in a homopolymeric region in the glpK gene was associated with drug resistance in clinical isolates. These studies indicate that reversible high-frequency variation in carbon metabolic pathways can produce phenotypically drug-tolerant clones and have a role in the development of resistance.


Subject(s)
Antitubercular Agents/pharmacology , Glycerol Kinase/genetics , Mycobacterium tuberculosis/genetics , Drug Resistance, Multiple, Bacterial/genetics , Microbial Sensitivity Tests , Mycobacterium tuberculosis/drug effects
4.
J Biol Chem ; 293(39): 14953-14961, 2018 09 28.
Article in English | MEDLINE | ID: mdl-30108176

ABSTRACT

Invasive Gram-negative bacteria often express multiple virulence-associated metal ion chelators to combat host-mediated metal deficiencies. Escherichia coli, Klebsiella, and Yersinia pestis isolates encoding the Yersinia high pathogenicity island (HPI) secrete yersiniabactin (Ybt), a metallophore originally shown to chelate iron ions during infection. However, our recent demonstration that Ybt also scavenges copper ions during infection led us to question whether it might be capable of retrieving other metals as well. Here, we find that uropathogenic E. coli also use Ybt to bind extracellular nickel ions. Using quantitative MS, we show that the canonical metal-Ybt import pathway internalizes the resulting Ni-Ybt complexes, extracts the nickel, and releases metal-free Ybt back to the extracellular space. We find that E. coli and Klebsiella direct the nickel liberated from this pathway to intracellular nickel enzymes. Thus, Ybt may provide access to nickel that is inaccessible to the conserved NikABCDE permease system. Nickel should be considered alongside iron and copper as a plausible substrate for Ybt-mediated metal import by enterobacteria during human infections.


Subject(s)
Copper/metabolism , Phenols/metabolism , Thiazoles/metabolism , Urinary Tract Infections/genetics , Uropathogenic Escherichia coli/genetics , Escherichia coli Infections/genetics , Escherichia coli Infections/microbiology , Genomic Islands/genetics , Humans , Iron/metabolism , Klebsiella/genetics , Klebsiella/pathogenicity , Urinary Tract Infections/microbiology , Uropathogenic Escherichia coli/pathogenicity , Yersinia pestis/genetics , Yersinia pestis/pathogenicity
5.
Nat Chem Biol ; 13(9): 1016-1021, 2017 Sep.
Article in English | MEDLINE | ID: mdl-28759019

ABSTRACT

Copper plays a dual role as a nutrient and a toxin during bacterial infections. While uropathogenic Escherichia coli (UPEC) strains can use the copper-binding metallophore yersiniabactin (Ybt) to resist copper toxicity, Ybt also converts bioavailable copper to Cu(II)-Ybt in low-copper conditions. Although E. coli have long been considered to lack a copper import pathway, we observed Ybt-mediated copper import in UPEC using canonical Fe(III)-Ybt transport proteins. UPEC removed copper from Cu(II)-Ybt with subsequent re-export of metal-free Ybt to the extracellular space. Copper released through this process became available to an E. coli cuproenzyme (the amine oxidase TynA), linking this import pathway to a nutrient acquisition function. Ybt-expressing E. coli thus engage in nutritional passivation, a strategy of minimizing a metal ion's toxicity while preserving its nutritional availability. Copper acquisition through this process may contribute to the marked virulence defect of Ybt-transport-deficient UPEC.


Subject(s)
Copper/classification , Escherichia coli , Phenols/metabolism , Thiazoles/metabolism , Copper/metabolism , Copper/toxicity , Escherichia coli/drug effects , Escherichia coli/metabolism
6.
Infect Immun ; 84(5): 1312-1319, 2016 05.
Article in English | MEDLINE | ID: mdl-26883590

ABSTRACT

The Yersinia high-pathogenicity island (HPI) is common to multiple virulence strategies used by Escherichia coli strains associated with urinary tract infection (UTI). Among the genes in this island are ybtP and ybtQ, encoding distinctive ATP binding cassette (ABC) proteins associated with iron(III)-yersiniabactin import in Yersinia pestis In this study, we compared the impact of ybtPQ on a model E. coli cystitis strain during in vitro culture and experimental murine infections. A ybtPQ-null mutant exhibited no growth defect under standard culture conditions, consistent with nonessentiality in this background. A growth defect phenotype was observed and genetically complemented in vitro during iron(III)-yersiniabactin-dependent growth. Following inoculation into the bladders of C3H/HEN and C3H/HeOuJ mice, this strain exhibited a profound, 10(6)-fold competitive infection defect in the subgroup of mice that progressed to high-titer bladder infections. These results identify a virulence role for YbtPQ in the highly inflammatory microenvironment characteristic of high-titer cystitis. The profound competitive defect may relate to the apparent selection of Yersinia HPI-positive E. coli in uncomplicated clinical UTIs.


Subject(s)
ATP-Binding Cassette Transporters/metabolism , Bacterial Proteins/metabolism , Cystitis/microbiology , Escherichia coli/pathogenicity , Phenols/metabolism , Thiazoles/metabolism , Virulence Factors/metabolism , ATP-Binding Cassette Transporters/genetics , Animals , Bacterial Proteins/genetics , Cystitis/pathology , Disease Models, Animal , Escherichia coli/genetics , Female , Gene Deletion , Genetic Complementation Test , Mice, Inbred C3H , Siderophores/metabolism , Virulence Factors/genetics
7.
J Biol Chem ; 290(31): 18967-74, 2015 Jul 31.
Article in English | MEDLINE | ID: mdl-26055720

ABSTRACT

Numerous pathogenic microorganisms secrete small molecule chelators called siderophores defined by their ability to bind extracellular ferric iron, making it bioavailable to microbes. Recently, a siderophore produced by uropathogenic Escherichia coli, yersiniabactin, was found to also bind copper ions during human infections. The ability of yersiniabactin to protect E. coli from copper toxicity and redox-based phagocyte defenses distinguishes it from other E. coli siderophores. Here we compare yersiniabactin to other extracellular copper-binding molecules and review how copper-binding siderophores may confer virulence-associated gains of function during infection pathogenesis.


Subject(s)
Copper/physiology , Host-Pathogen Interactions , Siderophores/physiology , Animals , Bacterial Infections/immunology , Bacterial Infections/microbiology , Coordination Complexes/chemistry , Coordination Complexes/metabolism , Escherichia coli/immunology , Escherichia coli/metabolism , Humans , Immunity, Innate , Yersinia/immunology , Yersinia/metabolism
8.
Metallomics ; 7(6): 1011-22, 2015 Jun.
Article in English | MEDLINE | ID: mdl-25824627

ABSTRACT

Uropathogenic Escherichia coli secrete siderophores during human infections. Although siderophores are classically defined by their ability to bind iron(III) ions, the virulence-associated siderophore yersiniabactin was recently found to bind divalent copper ions during urinary tract infections. Here we use a mass spectrometric approach to determine the extent of non-iron(III) metal interactions by yersiniabactin and its TonB-dependent outer membrane importer FyuA. In addition to copper, iron and gallium ions, yersiniabactin was also observed to form stable nickel, cobalt, and chromium ion complexes. In E. coli, copper(II) and all other non-iron(III) yersiniabactin complexes were imported by FyuA in a TonB-dependent manner. Among metal-yersiniabactin complexes, copper(II) yersiniabactin is predicted to be structurally distinctive and was the only complex not to competitively inhibit iron(III) yersiniabactin import. These results are consistent with yersiniabactin as part of a metallophore system able to prioritize iron(III) complex uptake in high copper environments.


Subject(s)
Metals/pharmacology , Phenols/pharmacology , Thiazoles/pharmacology , Bacterial Proteins/metabolism , Biological Transport/drug effects , Chromatography, Liquid , Models, Biological , Models, Molecular , Quantum Theory , Tandem Mass Spectrometry , Uropathogenic Escherichia coli/drug effects , Virulence/drug effects
9.
J Biol Chem ; 288(27): 20064-75, 2013 Jul 05.
Article in English | MEDLINE | ID: mdl-23689507

ABSTRACT

The Streptococcus pyogenes NAD(+) glycohydrolase (SPN) is secreted from the bacterial cell and translocated into the host cell cytosol where it contributes to cell death. Recent studies suggest that SPN is evolving and has diverged into NAD(+) glycohydrolase-inactive variants that correlate with tissue tropism. However, the role of SPN in both cytotoxicity and niche selection are unknown. To gain insight into the forces driving the adaptation of SPN, a detailed comparison of representative glycohydrolase activity-proficient and -deficient variants was conducted. Of a total 454 amino acids, the activity-deficient variants differed at only nine highly conserved positions. Exchanging residues between variants revealed that no one single residue could account for the inability of the deficient variants to cleave the glycosidic bond of ß-NAD(+) into nicotinamide and ADP-ribose; rather, reciprocal changes at 3 specific residues were required to both abolish activity of the proficient version and restore full activity to the deficient variant. Changing any combination of 1 or 2 residues resulted in intermediate activity. However, a change to any 1 residue resulted in a significant decrease in enzyme efficiency. A similar pattern involving multiple residues was observed for comparison with a second highly conserved activity-deficient variant class. Remarkably, despite differences in glycohydrolase activity, all versions of SPN were equally cytotoxic to cultured epithelial cells. These data indicate that the glycohydrolase activity of SPN may not be the only contribution the toxin has to the pathogenesis of S. pyogenes and that both versions of SPN play an important role during infection.


Subject(s)
Bacterial Proteins , Epithelial Cells/enzymology , NAD+ Nucleosidase , Streptococcal Infections/enzymology , Streptococcus pyogenes/enzymology , Adenosine Diphosphate/chemistry , Adenosine Diphosphate/genetics , Adenosine Diphosphate/metabolism , Bacterial Proteins/chemistry , Bacterial Proteins/genetics , Bacterial Proteins/metabolism , Cell Line , Epithelial Cells/microbiology , Epithelial Cells/pathology , Humans , NAD/chemistry , NAD/genetics , NAD/metabolism , NAD+ Nucleosidase/chemistry , NAD+ Nucleosidase/genetics , NAD+ Nucleosidase/metabolism , Species Specificity , Streptococcal Infections/genetics , Streptococcal Infections/pathology , Streptococcus pyogenes/genetics
SELECTION OF CITATIONS
SEARCH DETAIL
...